Lung cancer
Conditions
Interventions
PACIFIC Group (At least one cycle of concurrent chemotherapy during radiotherapy
radiotherapy dose of at least 56 Gy
at least 4 cycles of durvalumab immunotherapy maintenance after completion of chemoradiotherapy.):None
Induction Chemoimmunotherapy-Chemoradiotherapy-Immunotherapy Maintenance Group (Induction chemoimmunotherapy phase: At least one cycle of induction chemoimmunotherapy is required
Concurrent chemoradiotherapy phase: At least one cycle of concurrent chemotherapy is required, with a radiotherapy dose of at least 56 Gy
Immunotherapy maintenance phase: At least 4 cycles of immunotherapy maintenance are required after completion of chemoradiotherapy
the immunotherapy maintenance agent is a PD-1 inhibitor, with no restriction on the drug manufacturer.):None
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Pathologically confirmed stage III non-small cell lung cancer (NSCLC); 2) Negative for EGFR, ALK, and ROS1 gene mutations; 3) Received definitive radiotherapy (conventionally fractionated radiotherapy, with a total dose of at least 56 Gy); 4) Received at least 4 cycles of immune checkpoint inhibitor (ICI) maintenance therapy after completion of definitive chemoradiotherapy.
Exclusion criteria
Exclusion criteria: 1) Did not receive immune checkpoint inhibitor (ICI) maintenance therapy after completion of definitive chemoradiotherapy; 2) Received concurrent ICI during radiotherapy; 3) Did not receive concurrent chemoradiotherapy (defined as receiving at least one cycle of chemotherapy during radiotherapy); 4) Received anti-tumor therapy other than ICIs during the maintenance phase after chemoradiotherapy; 5) Presence of a second primary tumor; 6) Lost to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Treatment-related toxicity; | — |
Countries
China
Contacts
Public ContactDu Shisuo
Zhongshan Hospital, Fudan University
Outcome results
None listed